Cidofovir: A Review of its Use in Cytomegalovirus Retinitis in Patients with AIDS

Plosker, G.L.; Noble, S.
August 1999
Drugs;Aug1999, Vol. 58 Issue 2, p325
Academic Journal
Cidofovir is an antiviral nucleotide analogue with significant activity against cytomegalovirus (CMV) and other herpesviruses. The drug is indicated for the treatment of CMV retinitis, a sight-threatening condition, in patients with AIDS. Cidofovir has a long intracellular half-life which allows for a prolonged interval (2 weeks) between maintenance doses. In contrast, other intravenous treatment options for patients with CMV retinitis (i.e. ganciclovir and foscarnet) must be administered on a daily basis. The efficacy of intravenous cidofovir has been demonstrated in patients with AIDS and previously untreated CMV retinitis in multicentre randomised trials, and in a dose-finding study of cidofovir in patients with AIDS and previously treated relapsing CMV retinitis. Clinical trials have been relatively small (n ≤ 100 patients) and no studies have been conducted directly comparing intravenous cidofovir with the more established intravenous agents, ganciclovir or foscarnet. Indirect comparisons of clinical trial data suggest that intravenous cidofovir may have similar efficacy to intravenous ganciclovir or foscarnet in delaying progression of CMV retinitis. However, such comparisons must be made with caution because of potential differences in patient populations, data analysis techniques and interobserver variability in the masked assessment of retinal photographs. Nevertheless, intravenous cidofovir offers a less intrusive administration regimen than intravenous ganciclovir or foscarnet because of its prolonged dosage interval. Since therapy is life-long, patients receiving daily intravenous ganciclovir or foscarnet (but not cidofovir) usually require an indwelling central venous catheter and are therefore at increased risk of serious infection. The relatively long dosage interval for cidofovir may also have favourable implications in terms of overall treatment costs and patient quality of life, although specific data are very limited. Potentially irreversible nephrotoxicity is the major treatment-limiting adverse event associated with intravenous cidofovir in patients with AIDS-related CMV retinitis. Anterior uveitis/iritis has been reported frequently with intravenous cidofovir in postmarketing reports and a small number of patients have developed hypotony. Other treatment options for CMV retinitis are also associated with serious adverse events, and selection of pharmacotherapy will depend on a number of factors including retinitis lesion characteristics, patient quality-of-life issues and efficacy and tolerability profiles of available therapies. Conclusion: Although the extent of its use may be limited by its adverse event profile, cidofovir offers a useful addition to the limited number of drugs available for the treatment of CMV retinitis in patients with AIDS.


Related Articles

  • New drug may offer potent antiviral activity against human cytomegalovirus.  // Infectious Disease News;Oct2009, Vol. 22 Issue 10, p26 

    The article reports on a study by several researchers in Germany which investigated the anti-cytomegalovirus properties of AIC246, a new treatment for human cytomegalovirus.

  • Clearance of Cytomegalovirus Viremia after Initiation of Highly Active Antiretroviral Therapy. Boivin, Guy; LeBlanc, Roger P. // Journal of Infectious Diseases;3/1/2000, Vol. 181 Issue 3, p1216 

    Studies the clearance of cytomegalovirus (CMV) viremia after initiation of highly active antiretroviral therapy (HAART). HIV and CMV loads in patients who received HAART; Rate of clearance of CMV viremia after HAART; CD4[sup +] cell counts of patients after the initiation of HAART.

  • Putting a Hold on CMV. Helquist, Michael // Advocate;2/3/87, Issue 465, p23 

    Discusses the possible effectiveness of an antiviral drug called DHPG in treating cytomegalovirus (CMV) retinitis and possibly against CMV pneumonia and CMV encephalitis. Estimated percentage of the gay population that has been infected with CMV; Use of DHPG on a compassionate use basis for...

  • Biliary Atresia and Cytomegalovirus and Response to Valganciclovir. Shah, Ira; Bhatnagar, Sushmita // Indian Pediatrics;Jun2012, Vol. 49 Issue 6, p484 

    Biliary atresia has been commonly reported with cytomegalovirus (CMV) infection. CMV positive patients may present with a later onset however long term outcome is similar to non-CMV patients. There are very few case reports of role of antivirals in CMV and biliary atresia. We treated a 2 month...

  • Chimerix Aiming to 'SUPPRESS' CMV Infection in Phase III. Boggs, Jennifer // BioWorld Today;9/10/2013, Vol. 24 Issue 173, p1 

    The article reports on the Phase III SUPPRESS trial testing being done by Chimerix Inc. on its oral nucleotide analogue lipid-conjugate brincidofovir (CMX001) for prevention of cytomegalovirus infection in hematopoietic cell transplant patients. The success of the initial public offering (IPO)...

  • Ulcerative colitis after Cytomegalovirus Infection. Aminianfar, Mohammad; Saeedi, Ali Asghar; Darvishi, Mohammad; Faraji, Siroos // Zahedan Journal of Research in Medical Sciences;Jun2014, Vol. 16 Issue 6, p95 

    The article presents a case study of a 21-year-old man with ulcerative colitis, sigmoidoscopic appearance and histology of colonic biopsy specimens. Cytomegalovirus (CMV) 65 pp antigenemia assays of the patient confirmed CMV viraemia and intravenous ganciclovir was administered. Cytomegalovirus...

  • Dynamics of Cytomegalovirus (CMV)--Specific T Cells in HIV-1--Infected Individuals Progressing to AIDS with CMV End-Organ Disease. Bronke, Corine; Palmer, Nanette M.; Jansen, Christine A.; Westerlaken, Geertje H. A.; Polstra, Abeltje M.; Reiss, Peter; Bakker, Marqreet; Miedema, Frank; Tesselaar, Kiki; Van Baarle, Debbie // Journal of Infectious Diseases;3/15/2005, Vol. 191 Issue 6, p873 

    Background. Since cytomegalovirus (CMV) infection can cause serious clinical complications in immunocompromised individuals, we assessed cellular immune requirements for protection against CMV end-organ disease (CMV-EOD) in human immunodeficiency virus type 1 (HIV-1) infection. Methods....

  • Long term visual outcomes of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy. Goldberg, D.E.; Wang, H.; Azen, S.P.; Freeman, W.R. // British Journal of Ophthalmology;Jul2003, Vol. 87 Issue 7, p853 

    Background: Healed cytomegalovirus (CMV) retinitis in the setting of highly active antiretroviral therapy (HAART) is complicated by inflammatory sequelae and vision loss. Aim: To determine the long term visual outcome of AIDS patients with CMV retinitis who received HAART. Methods: 90 eyes of 63...

  • NATIONAL.  // Advocate;11/5/91, Issue 589, p30 

    Presents news briefs related to AIDS in the U.S. as of November 11, 1991. Congressional approval of a measure that would require states to adopt government guidelines regarding physicians who test positive for HIV; Government approval of the drug foscavir for treatment of AIDS-related...

  • Anti-cytomegalovirus therapy may not be needed upon immune recovery. Pagnani, Michelle; Srivastava, Sunil K. // Ocular Surgery News;2/25/2012, Vol. 30 Issue 4, special section p7 

    The article reports on the findings of a study which reinforced U.S. Public Health Service guidelines about the discontinuation of anti-cytomegalovirus (CMV) therapy after immune recovery in AIDS patients. Doctor Janet T. Holbrook stated that CMV disease is more common in neonates due to their...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics